JIN YANSHAN

Ms. JIN YANSHAN


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MJMengying Jiang
Mengying Jiang
YSYi-zuo Song
Yi-zuo Song
LHLiu Hejing
Liu Hejing
JYJIN YANSHAN
JIN YANSHAN
RLRuyi Li
Ruyi Li
XZXueqiong Zhu
Xueqiong Zhu
Ferroptosis exhibits a potent antitumor effect and dihydroorotate dehydrogenase (DHODH) has recently been identified as a novel ferroptosis defender. However, the role of DHODH inhibition in cervical cancer cells is unclear, particularly in synergy with cisplatin via ferroptosis. Herein, shRNA and brequinar were used to knock down DHODH and directly inhibit DHODH, respectively. Immunohistochemistry and Western blotting assays were performed to measure the expression of proteins. CCK-8 and colony formation assays were employed to assess the cell viability and proliferation. Ferroptosis was monitored through flow cytometry, the malondialdehyde assay kit and JC-1 staining analyses. The nude mouse xenograft model was generated to examine the effect of combination of DHODH inhibition and cisplatin on tumor growth in vivo. The expression of DHODH was increased in cervical cancer tissues. DHODH inhibition inhibited the proliferation and promoted the ferroptosis in cervical cancer cells. A combination of DHODH inhibition and cisplatin synergistically induced both in vitro and in vivo ferroptosis and downregulated the ferroptosis defender mTOR pathway. Therefore, the combination of DHODH inhibition and cisplatin exhibits synergistic effects on ferroptosis induction via inhibiting the mTOR pathway could provide a promising way for cervical cancer therapy.

10 June 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JLJingjing Lu
Jingjing Lu
YPYiming Pan
Yiming Pan
LLLu Li
Lu Li
LCLili Chu
Lili Chu
JYJIN YANSHAN
JIN YANSHAN
Objective: This study aimed to assess the impact of implementing the diagnosis-related groups (DRGs) payment system on hospitalization costs and medical service outcomes at a single institution. The objective was to identify effective cost-saving strategies and guide healthcare practices to support the ongoing adoption of the DRGs system.Methods: This retrospective study included 616 patients, categorized into three groups based on the payment system in effect during their treatment: a 6-month period under fee-for-service (FFS), a 6-month period following the trial implementation of DRGs (TI-DRGs), and a 6-month period after the official implementation of DRGs (OI-DRGs). Each group was further divided into two subgroups according to the surgical intervention received (either laparoscopic myomectomy or laparoscopic hysterectomy). Data collected included total medical costs, examination fees, surgical costs, medication and supply expenses, length of hospital stay, operation time, intraoperative blood loss, incidence of postoperative anemia, and frequency of blood transfusions.Results: Total medical costs in the OI-DRGs group were 6.6 and 9.0% higher than those in the FFS and TI-DRGs groups, respectively (p < 0.001). Examination costs followed a similar pattern, with the OI-DRGs group showing increases of 5.3 and 12.3% compared to the FFS and TI-DRGs groups (p < 0.001). Operation costs also varied significantly among the three groups; the OI-DRGs group incurred 17.1 and 10.5% higher costs than the FFS and TI-DRGs groups, respectively (p < 0.001). There were no significant differences among the groups in terms of hospital stay duration, operation time, or intraoperative blood loss. In the FFS group, 57 patients developed postoperative anemia and 14 required blood transfusions; in the TI-DRGs group, 52 patients developed anemia and 16 received transfusions; and in the OI-DRGs group, 74 patients developed anemia with 16 requiring transfusions. However, these differences were not statistically significant.Conclusion: In summary, the implementation of DRGs for laparoscopic uterine leiomyoma surgery did not lead to a significant reduction in total medical costs. Overall costs were influenced by multiple factors, including the DRG phase, length of stay, type of surgery, and the presence of concurrent procedures. The findings from our single-center study differ from the mainstream view, highlighting that the effects of DRG implementation can be highly context-specific, shaped by local policies, hospital practices, and patient case-mix, which may limit the generalizability of these results beyond our institution or region.